Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

News SummaryMost relevantAll newsSector newsTweets

FDA Approves Breast-Cancer Drug

share with twitter share with LinkedIn share with facebook
share via e-mail
02/22/2013 | 06:05pm CEST

--Drug packs Roche's Herceptin with chemotherapy agent

--Drug approved for use as a first-line, or initial treatment for advanced breast cancer

WASHINGTON--The U.S. Food and Drug Administration Friday approved a powerful new type of drug that will be marketed by Roche Holding AG (ROG.VX, RHHBY) to treat breast cancer.

The drug called, Kadcyla, combines Roche's existing cancer drug, Herceptin, with a powerful chemotherapy agent, and is meant to treat certain types of breast cancer that have spread to other parts of the body.

Herceptin targets a protein called HER2 found on tumors in about 20% to 25% of breast-cancer patients. The two other components of Kadcyla, both developed by ImmunoGen Inc. (>> ImmunoGen, Inc.), are a chemotherapy agent called emtansine that is too potent to be delivered as a conventional medicine, and a linker that connects the two drugs. Herceptin then delivers the package to the tumor cell, where it releases the toxic cargo to kill the cancer.

The FDA's approval of Kadcyla, which was previously known as T-DM1, triggers a $10.5 million payment to ImmunoGen by Roche. ImmunoGen will also receive royalties on sales of up to 5%.

Analysts said the approval was broader than expected. The drug can be marketed for initial treatment rather than just in patients who've tried other therapies, creating a "significantly larger patient population," said Simos Simeondis, an analyst at Cowen and Company.

Roche's Genentech unit said Kadcyla will be available to patients in about two weeks. The drug will be priced at $9,800 a month. The company said there will be a patient-assistance program to help pay for the product.

Agents like Kadcyla are called antibody-drug conjugates and they are the focus of intense interest in the pharmaceutical industry. Roche's Genentech unit has 25 such agents under development for different cancers, including eight in human studies.

The first such agent to gain FDA approval was Seattle Genetics Inc.'s (>> Seattle Genetics, Inc.) Adcetris, for Hodgkin's Lymphoma and another rare cancer. That company and ImmunoGen are each collaborating with big pharmaceutical firms including Bayer AG (BAYRY, BAYN.XE), Eli Lilly & Co. (>> Eli Lilly & Co.), GlaxoSmith Kline PLC (GSK, GSK.LN), Pfizer Inc. (>> Pfizer Inc.), Sanofi (>> Sanofi SA) to develop several types of new cancer drugs.

The approval of Kadcyla was based on a study of about 1,000 women with HER2-positive breast cancer who had been treated previously with Herceptin and a traditional chemotherapy drug. About half of the women were then treated with T-DM1 and the other half were treated with a combination of Xeloda, another Roche drug, and GlaxoSmithKline's Tykerb. The study showed women receiving Kadcyla lived for an average of 31 months, which was about six months longer than women being treated with Xeloda and Tykerb.

However, like other cancer drugs Kadcyla has the potential to cause serious and life-threatening side effects from liver damage or heart problems. The drug can also cause severe birth defects so doctors need to make sure women of child-bearing age aren't pregnant before administering the product.

--Joseph Walker contributed to this story.

Write to Jennifer Corbett Dooren at jennifer.corbett@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ROCHE HOLDING LTD.
11:56a ROCHE : New target could yield treatment for Alzheimer`s, ALS and more
08/17 ROCHE : Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Cla..
08/16 FIBROGEN : Galapagos and FibroGen drugs offer hope in IPF
08/16 FOUNDATION MEDICINE : Cancer Treatment Centers of America and Foundation Medicin..
08/15 ROCHE : Acquires MySugr
08/15 CHUGAI PHARMACEUTICAL : Announcement of a Commencement of Arbitration against Ch..
08/15DJROCHE : Drug-Trial Previews Burn Investors -- WSJ
08/14 ROCHE : Special Notice - 66-- Intent to Sole Source / Roche Diagnostics Corporat..
08/14DJROCHE : Some Investors Feel Burned by Drugmakers' Clinical-Trial Reports
08/12 ROCHE : KIT, solution and material, compatible with use in blood and PH hemogaso..
More news
News from SeekingAlpha
07:01a New Orphan Drug designations in U.S.
08/17 House Dems look into MS med prices, seven drug makers contacted
08/16 Biogen's Alzheimer's Hope Tops The Sector's Most Valuable Pipeline Projects
08/16 UBS still optimistic that Bristol-Myers can still be a player in first-line k..
08/15 Roche's Ocrevus OK'd in Canada for RRMS
Financials ( CHF)
Sales 2017 53 295 M
EBIT 2017 18 366 M
Net income 2017 11 164 M
Debt 2017 8 833 M
Yield 2017 3,51%
P/E ratio 2017 18,30
P/E ratio 2018 16,65
EV / Sales 2017 4,12x
EV / Sales 2018 3,88x
Capitalization 210 521 M
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 280  CHF
Spread / Average Target 14%
EPS Revisions
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.5.37%218 752
JOHNSON & JOHNSON15.48%357 079
NOVARTIS10.59%218 545
PFIZER1.45%196 221
SANOFI7.62%122 613